Q-TWiST favours epirubicin-containing regimen in breast cancer

Author：

ISSN： 1173-5503

Source： PharmacoEconomics and Outcomes News, Vol.1, Iss.472, 2005-01, pp. : 13-13

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Q-TWiST Analysis of Cyclophosphamide, Epirubicin, Fluorouracil versus Cyclophosphamide, Methotrexate, Fluorouracil Treatment for Premenopausal Women with Node-Positive Breast Cancer

By Davide Radice Alberto Redaelli

PharmacoEconomics, Vol. 23, Iss. 1, 2005-01 ,pp. : 69-75

Adis International

Access to resources Recommend Favorite

Q-TWiST Analysis of Patients Receiving Temsirolimus or Interferon Alpha for Treatment of Advanced Renal Cell Carcinoma

By Zbrozek Arthur S.

PharmacoEconomics, Vol. 28, Iss. 7, 2010-07 ,pp. : 577-584

Adis International

Access to resources Recommend Favorite

Epirubicin makes a difference for women with early breast cancer

Inpharma, Vol. 1, Iss. 1563, 2006-01 ,pp. : 1-1

Adis International

Access to resources Recommend Favorite

Gemcitabine/epirubicin/docetaxel effective in early breast cancer

Inpharma, Vol. 1, Iss. 1471, 2005-01 ,pp. : 11-11

Adis International

Access to resources Recommend Favorite

Epirubicin plus vinorelbine useful in advanced breast cancer

Inpharma, Vol. 1, Iss. 1453, 2004-01 ,pp. : 10-10

Adis International

Access to resources Recommend Favorite